The popularity of copyright’s blockbuster initially sparked a period of growth for major pharmaceutical companies, but recent changes present a uncertain scenario for those considering a stake. Off-patent versions are reducing profits, and continued litigation add additional risk to the equation. While some companies might still gain from relate… Read More